Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.

ABSTRACT:

Importance

The addition of daratumumab to backbone multiple myeloma (MM) regimens is associated with improved response rates and progression-free survival (PFS). Whether improved outcomes are also associated with this regimen among patients with cytogenetically defined high-risk MM (HRMM) remains unclear.

Objective

To measure PFS associated with adding daratumumab to backbone MM regimens among patients with HRMM.

Data sources

For this systematic review and meta-analysis, MEDLINE, Embase, PubMed, Scopus, Web of Science Core Collection, Cochrane Library, clinical trials registries, and meeting libraries were searched from inception to January 2, 2020, using terms reflecting multiple myeloma and daratumumab.

Study selection

Included studies were phase 3 randomized

SUBMITTER: Giri S 

PROVIDER: S-EPMC7516804 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature